bioRxiv · 20 Nov 2026
TEAD Palmitoylation Inhibitors are Brain Penetrant and Enhance Survival in Preclinical Models of Recurrent Glioblastoma in Combination with Standard-of-Care Therapy
Thenzing Juda Silva Hurtadoh-index 2, Balagopal Pai, Mohammad Imran K. Khan, Debdatta Halder, Anne Marie Barrette, Timothy E Richardson, Anirudh Sattiraju, Roland H Friedel, Hongyan Zou, Dolores Hambardzumyan, Raymund L Young, Tracy T Tang, Nadejda M Tsankova
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Purpose: Oncogenic addiction to YAP-TEAD signaling drives adaptive plasticity, therapeutic resistance, invasion and tumor progression in many cancers, including in glioblastoma (GBM), and represents an actionable vulnerability to explore as adjuvant therapy during tumor recurrence. This study evaluated the translational potential of orally bioavailable Vivace Therapeutics (VT) TEAD palmitoylation inhibitors in preclinical GBM models. Experimental Design: The effects of VT103 and VT104 on GBM proliferation, migration, and TEAD activity were first assessed across patient-derived GBM cell lines with diverse genomic drivers. The drugs pharmacokinetics (PK) and biodistribution were measured using mass spectrometry in mice bearing patient-derived orthotopic xenograft (PDX) GBM. Therapeutic efficacy was evaluated in two genetically distinct PDX models of recurrent GBM, administering VT104 as monotherapy or in combination with standard-of-care radiotherapy plus temozolomide (RT+TMZ). Results: VT104/VT103 treatment significantly impaired GBM proliferation and migration in-vitro, with concomitant downregulation of TEAD-target expression. PK studies confirmed sustained VT104 plasma levels and robust brain biodistribution in PDX mice, with brain:plasma ratio >150% at therapeutic dosing without systemic toxicity. While VT104 monotherapy showed modest anti-tumor effects, combination therapy (VT104+RT+TMZ) significantly extended overall survival in both recurrent GBM PDX models. The survival benefit was most prominent in EGFR-mutant GBM and corresponded to significant decrease in overall and infiltrative tumor burden. Mechanistically, VT104 potentiated TMZ-dependent {gamma}-H2AX genotoxic stress and RT+TMZ synergized with VT104 to abolish TEAD activity. Conclusion: Integrating YAP-TEAD inhibition with standard therapy introduces a clinically-relevant paradigm for synergistic treatment in recurrent GBM that both inhibits tumor infiltration and reduces therapeutic resistance to chemoradiation.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Thenzing Juda Silva Hurtado has the highest h-index among the authors (2).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.